Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 18/20 | 0.49 |
| ▸ | CTRC | Q99895 | 4/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6750158 | 0.99 | F2 (0.48) | F2CTRCPRSS2F10KDM4E | |
| SCHEMBL6749897 | 0.92 | F2 (0.50) | F2CTRCPRSS2F10ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6747626 | 0.91 | F2 (0.49) | F2CTRCPRSS2F10ALDH1A1 | |
| SCHEMBL6747827 | 0.89 | F2 (0.51) | F2CTRCPRSS2F10 | |
| Hydrochloric Acid SCHEMBL6749351 | 0.88 | F2 (0.51) | F2CTRCPRSS2F10 | |
| SCHEMBL6745957 | 0.88 | F2 (0.54) | F2CTRCPRSS2F10 | |
| SCHEMBL6745983 | 0.88 | F2 (0.54) | F2CTRCPRSS2F10 | |
| Hydrochloric Acid SCHEMBL6749884 | 0.87 | F2 (0.53) | F2CTRCPRSS2F10 | |
| Hydrochloric Acid SCHEMBL6746005 | 0.87 | F2 (0.53) | F2CTRCPRSS2F10 | |
| SCHEMBL6745859 | 0.87 | F2 (0.65) | F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730783-B2 | REACTING AMINOGUANIDINE WITH CARBONYL COMPOUND TO FORM AMIDINOHYDRAZONE; REDUCTION; REACTING WITH ALKOXYAMINE; GUANIDINYLATION; ANTICOAGULANTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | claimed |
| US-20040002539-A1 | Process for preparing aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-01 | — | — | US | claimed |
| US-6638931-B1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-10-28 | — | — | US | claimed |
| EP-0944590-B1 | AMINOGUANIDINES AND ALKOXYGUANIDINES AS PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2002-03-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002539-A1 | Process for preparing aminoguanidines and alkoxyguanidines as protease inhibitors | F9, PLG, MMP9 | F2 27/4885CTRC 69/4885PRSS2 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.